POLYSERP MENA is a single source treatment option, covering 27 medically significant species in a single, broad-spectrum, freeze-dried formula. Designed for the field, POLYSERP is a safe, affordable, and effective treatment, bringing definitive care far-forward.
The low total protein content and patented purification, fragmentation and lyophilization process make POLYSERP among the safest products of its kind. POLYSERP MENA has a total incidence of possible severe early adverse reactions such as anaphylaxis of just 1%. POLYSERP is designed to be administered by direct IV push in low resource environments.
POLYSERP antivenoms are broad-spectrum, regionally specific formulations that have been carefully designed to meet the challenges of the austere medicine environment.
EXPLORE PEER-REVIEWED DATA
Download the MENA Package Insert.
GET IN TOUCH
Contact us for orders.
For direct sales and quotes, contact our US-based team at sales@polyserptherapeutics.com.
To report suspected adverse reactions, contact POLYSERP™ Therapeutics
at pharmacovigilance@polyserptherapeutics.com.